Possible association of ABCB1:c.3435T>C polymorphism with high-density-lipoprotein-cholesterol response to statin treatment - a pilot study
| Autor: | Iwona Hornowska, Jeremy Clark, Anna Sałacka, Krzysztof Safranow, Mariusz Kaczmarczyk, Agnieszka Bińczak-Kuleta |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Simvastatin Atorvastatin Pilot Projects ABCB1 transporter chemistry.chemical_compound High-density lipoprotein lcsh:R5-920 biology Homozygote Middle Aged Lipids Biochemistry HMG-CoA reductase Female lipids (amino acids peptides and proteins) lcsh:Medicine (General) medicine.drug medicine.medical_specialty ATP Binding Cassette Transporter Subfamily B Statin Genotype medicine.drug_class P-glycoprotein Diabetes mellitus Internal medicine medicine Humans Pyrroles HMG-CoA reductase inhibitors RNA Messenger Molecular Biology Alleles Triglycerides Aged Polymorphism Genetic Cholesterol business.industry Cholesterol HDL medicine.disease Endocrinology chemistry Heptanoic Acids Multivariate Analysis biology.protein Hydroxymethylglutaryl-CoA Reductase Inhibitors business Body mass index |
| Zdroj: | Bosnian Journal of Basic Medical Sciences, Vol 14, Iss 3 (2014) ResearcherID |
| ISSN: | 2831-090X 2831-0896 |
| DOI: | 10.17305/bjbms.2014.3.43 |
| Popis: | The gene product ABCB1 (formerly MDR1 or P-glycoprotein) is hypothesized to be involved in cholesterol cellular trafficking, redistribution and intestinal re-absorption. Carriers of the ABCB1:3435T allele have previously been associated with decreases in ABCB1 mRNA and protein concentrations and have been correlated with changes in serum lipid concentrations. The aim of this study was to investigate possible association between the ABCB1:3435T>C polymorphism and changes in lipids in patients following statin treatment. Outpatients (n=130) were examined: 43 men (33%), 87 women (67%): treated with atorvastatin or simvastatin (all patients with equivalent dose of 20 or 40 mg/d simvastatin). Blood was taken for ABCB1:3435T>C genotyping, and before and after statin treatment for lipid concentration determination (total cholesterol, high-density-lipoprotein-cholesterol (HDL-C), triglycerides). Change (Δ) in lipid parameters, calculated as differences between measurements before and after treatment, were analyzed with multiple regression adjustments: gender, diabetes, age, body mass index, equivalent statin dose, length of treatment. Univariate and multivariate analyses showed significant differences in ΔHDL-C (univariate p=0.029; multivariate p=0.036) and %ΔHDL-C (univariate p=0.021; multivariate p=0.023) between patients with TT (-0.05 ± 0.13 g/l; -6.8% ± 20%; respectively) and CC+CT genotypes (0.004 ± 0.15 g/l; 4.1 ± 26%; respectively). Reduction of HDL-C in homozygous ABCB1:3435TT patients suggests this genotype could be associated with a reduction in the benefits of statin treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|